Amneal Pharmaceuticals, Inc.
AMRX
$17.09
$0.040.24%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 10.20% | -11.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.20% | -11.27% | |||
| Cost of Revenue | 14.81% | -22.10% | |||
| Gross Profit | 4.35% | 7.71% | |||
| SG&A Expenses | 7.10% | -5.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -1,928.13% | -6,300.00% | |||
| Total Operating Expenses | 11.89% | -16.96% | |||
| Operating Income | 3.24% | 23.48% | |||
| Income Before Tax | -11.46% | 45.15% | |||
| Income Tax Expenses | -36.76% | -61.57% | |||
| Earnings from Continuing Operations | -10.75% | 57.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 24.09% | -8.60% | |||
| Net Income | -7.38% | 77.49% | |||
| EBIT | 3.24% | 23.48% | |||
| EBITDA | 4.98% | 12.74% | |||
| EPS Basic | -8.32% | 76.68% | |||
| Normalized Basic EPS | 16.01% | 67.49% | |||
| EPS Diluted | -5.26% | 73.83% | |||
| Normalized Diluted EPS | 17.48% | 68.04% | |||
| Average Basic Shares Outstanding | 1.01% | 0.50% | |||
| Average Diluted Shares Outstanding | -0.25% | 0.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||